Key Takeaways
- Earnings inflection, not just pipeline: EBITDA surged 67% and margins expanded 500 bps to 14%, driven by cost discipline and operating leverage, even before the novel antibiotic portfolio begins to scale.
- ZAYNICH is the central value driver: Phase 3 data showed 20% superiority, a rare outcome for antibiotics; US filing is imminent, and the company is building a parallel own-commercialization path to strengthen its outlicensing hand.
- Novo Nordisk's insulin exit opens a window: The global leader discontinuing disposable pens creates a supply gap Wockhardt intends to fill, with a plan to double capacity in 24 months and build a new facility.
- Miqnaf launch is a live test of commercial execution: India's first novel macrolide in 30 years launched in May with a disciplined specialist-only strategy, and management is applying hard lessons from the EMROK experience.
- What to watch next quarter: The US FDA filing for ZAYNICH, any outlicensing progress or CEO hire for the US organization, and early prescription data from the Miqnaf launch.
ZAYNICH: The Lead Asset
- Clinical profile: The global Phase 3 trial delivered 20% superiority over the standard of care, a result management called "truly outstanding" for a space where non-inferiority is the norm. A Phase 2 study in India against carbapenem-resistant organisms showed over 90% efficacy, and 51 lives have been saved via compassionate use in the last 18 months.
- Regulatory path: Filed with DCGI in March 2025; approval is expected at the beginning of next year, with Indian market entry 3-4 months after that. US FDA filing is planned for the coming quarter, with a 9-12 month review implying a potential US launch by mid-next year. European and emerging market filings are targeted for H2 this year, with launches in H2 next year.
- Manufacturing: Western market supply will use existing suppliers with adequate capacity. For India and emerging markets, API is manufactured in-house in India, with formulation done via third-party manufacturing. Current capacity is adequate for the next 2-3 years, with build-up planned as demand scales.
- Commercialization strategy: Management is running two parallel tracks: outlicense to big pharma if valuation is attractive, or build its own organization. A CEO for the US entity may be hired in the next few months. The Chairman framed this explicitly as a negotiating lever: having a credible own-commercialization alternative forces suitors to meet the company's value expectations.
Habil Khorakiwala: "if I have to get more value for my proposition, I have to be very serious of creating my own organization as an alternative. So that -- it's not that for people come and give me a rate. But if I have expectation higher than that, I have to say that I have an alternative available if I believe this is a value we will."
Miqnaf: The India Launch Underway
- Product significance: Miqnaf is the first new antibiotic in the macrolide class in 30 years, discovered and developed entirely in India. It launched on 27th May 2025 with a dedicated business unit.
- Launch strategy: For the first 6 months, promotion is restricted to chest specialists only, so that specialist endorsement builds a long, sustainable product life. About one-third of patients chest specialists see are untreatable by any oral treatment and are normally referred to hospitals for injectables. After 6 months, coverage expands to consulting physicians, ENTs and pediatricians, but promotion will stay with specialists for 3-4 years and will not go to GPs. The 3-day treatment costs INR 3,000, which management argues is cost-effective compared to hospitalization.
- Organizational learning applied: Management acknowledged that the EMROK launch was a difficult learning experience because the company was new to it. For Miqnaf and ZAYNICH, the organization has been rebuilt with a top team from multinational companies who have experience launching new drugs.
- Global ambitions: The initial focus is India and emerging markets; the plan is to take Miqnaf to the rest of the world after 3-5 years.
Murtaza Khorakiwala: "after 30 years there is a new antibiotic in the macrolide class which is there... Wockhardt has introduced India discovered, India R&D, India developed clinical trial done in India, Maa product for the Indian market which we will now take outside India into the rest of the world after 35 years"
Insulin & Biosimilar Opportunity
- Novo Nordisk catalyst: Novo Nordisk, the largest insulin company globally, has decided to discontinue its disposable insulin pens and cartridges to focus manufacturing capacity on semaglutide and other GLP-1 analogs where demand exceeds supply. This opens up market space for existing insulin players, and Wockhardt is positioned to capture share.
- Capacity expansion: The company plans to double insulin capacity over the next 24 months and put up a new facility. Broader biotech capacity doubling is targeted over 24-36 months.
- Portfolio development: The biosimilar business grew 20% this year. Over the next 3 years, growth is expected from the diabetes biosimilar portfolio including insulin glargine. Over a 3-5 year horizon, the company is developing more insulin analogs and GLP-1 analogs like semaglutide. Aspart has been filed for marketing approval with DCGI; Lispro is further up in development.
- New biotech business: Business development, partnerships and collaborations equivalent to roughly $30 million have been developed for the next 24 months.
Financial Turnaround & Cost Discipline
- Margin expansion: EBITDA margin expanded 500 bps from 9% to 14%, with sales growing 5% while costs stayed nearly flat year-on-year. A dedicated team monitors cost reduction initiatives including restructuring manufacturing from external to internal, energy cost reduction, and focused wastage reduction with improved MIS and operational team sensitization.
- Debt transformation: Net debt reduced from INR 882 crores in FY22 to INR 64 crores in FY25, aided by the INR 1,000 crore QIP.
- R&D spending outlook: Management expects to continue spending approximately USD 200-250 million or more on new drug discovery, and believes cash flow from operations will be more than adequate to fund it.
- Growth ambition: Management expects to double the business in the next 3 years, with strong performance continuing if not accelerating as the novel antibiotic portfolio accesses larger markets in India, emerging markets, the US and Europe.
Pipeline & Other Assets
- WCK 5222 (ZAYNICH): The investigational break point of 64 milligrams is among the highest of any antibiotic covering gram-negative organisms. Entire manufacturing, API and formulated product, is done in Europe at USFDA-approved facilities.
- EMROK: Has treated 100,000 patients successfully and achieved approximately 10% market share. The company is expanding into other indications and to other specialties and customers in India, with promising results expected from the initial expansion.
- Odrate: A Phase 1 clinical trial in the US, sponsored and funded by the NIH, has been completed with good results.
- Foviscu (4282): Phase 2 clinical trial is being completed.
- Saudi Arabia BMP: Received breakthrough medicinal product category designation for pneumonia treatment.
- Scientific team model: The scientific team that discovered the drug, requiring about 15 disciplines, works as an integrated unit rather than in silos. This model has been extended to business operations, with scientists kept as part of overall business development so that the scientific profile remains "second to none."
Habil Khorakiwala: "So they are totally in sync, because scientists know much more of the molecule because they have lived with the molecule for last 10-15 years. So whatever they plan to transfer the knowledge to medical or commercial people it will not be same level. So we are keeping them as a part of overall business development, so that our scientific profile, whether in India or US or anywhere will be second to none"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ZAYNICH US filing | File with USFDA | Coming quarter |
| ZAYNICH US launch | Approval takes 9-12 months from filing | Middle of next year |
| ZAYNICH India approval | Filed March 2025; approval expected | Beginning of next year |
| ZAYNICH India launch | 3-4 months post-approval | Middle of next year |
| ZAYNICH Europe & EM filing | File in H2 this year | H2 this year |
| ZAYNICH Europe & EM launch | Dependent on approval time | H2 next year |
| Insulin capacity doubling | Double capacity and put up new facility | Next 24 months |
| Biotech capacity doubling | Double capacity | Next 24-36 months |
| Business doubling | Double the overall business | Next 3 years |
| Miqnaf promotion expansion | Expand to consulting physicians, ENTs, pediatricians | After 6 months from launch |
| Miqnaf specialist restriction | Promotion restricted to specialists, not GPs | Next 3-4 years |
| R&D spending | Continue at USD 200-250 mn or more | Ongoing |
| US CEO hire | Potential hire for own US organization | Next few months |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹3,033 cr, +5% YoY |
| EBITDA | ₹418 cr, +67% YoY |
| EBITDA margin | 14%, expanded 500 bps from 9% |
| Net debt | ₹64 cr, reduced from ₹882 cr in FY22 |
| Net debt to equity | 0.01% |
| Cash available | ₹600 cr |
| Equity | ₹4,600 cr, up from ₹3,600 cr |
| India branded business growth | +4% YoY |
| UK business growth | +8% YoY |
| Emerging markets business growth | +10% YoY |
| Biosimilar business growth | +20% YoY |
| EMROK market share | ~10% in India |
| EMROK cumulative patients treated | 100,000 |
| ZAYNICH global Phase 3 superiority | 20% over existing treatment |
| ZAYNICH Phase 2 efficacy vs carbapenem-resistant organisms | >90% |
| ZAYNICH compassionate-use lives saved | 51 in last 1.5 years |
| Miqnaf Phase 3 efficacy | 96.7% |
| Miqnaf treatment duration | 3 days, vs 5–7 days for conventional therapies |
| ZAYNICH global addressable patients | ~0.2 cr annually |
| ZAYNICH US and Europe addressable market | $7 bn, 371,000 cases |
| ZAYNICH India addressable market | ₹17,000 cr, ~0.1 cr cases |
| Miqnaf India addressable market | ₹10,800 cr, 9.6 cr prescriptions |
| Diabetes portfolio emerging-market opportunity | $3 bn |
| R&D spend on new drug discovery | $200–250 mn annually, expected to continue |
| QIP raised | ₹1,000 cr |